An interventional study of Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads) in Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 and Spinal Muscular Atrophy Type II, sponsored by Marco Capogrosso. Completed at 1 site in United States. Open to participants aged 16 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Marco Capogrosso · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States — 3 open to participants now, 7 under way, 2 of them phase 3. Spinal Muscular Atrophies of Childhood · United States.
Among the 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 with no phase, and was the 19th registered.
61 studies on the registry are indexed under Spinal Muscular Atrophies of Childhood; 18 are open to participants now.
Browse Spinal Muscular Atrophies of Childhood studies →3 of the 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States are open now. Recruiting first, the newest first:
Jacqueline Montes · Sites in United States
Ages 8–50
Scholar Rock, Inc. · Sites in United States, Belgium, France and 4 more countries
Ages up to 2
Columbia University · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Spinal Muscular Atrophies of Childhood studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 16 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 4
First in 1986; this study’s year is marked. 2 started in 2024.
This study's enrollment of 3 is below the median of 15 across 41 interventional studies indexed under Spinal Muscular Atrophies of Childhood.
Median enrollment 40 across the 13 interventional studies, 88 across the 10 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 23 have an industry lead sponsor. The 10 most frequent:
Marco Capogrosso is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Marco Capogrosso has 2 studies filed under Spinal Muscular Atrophies of Childhood — fewer than ten, so there is no comparison to draw.
1 of the studies in Spinal Muscular Atrophies of Childhood with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400198Jacqueline MontesGait and Bone Health in SMA | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical inputs. This pilot will test if SCS can show evidence to improve motor deficits in people with Type 2, 3, or 4 spinal muscular atrophy (SMA). The investigators will enroll up to six subjects with Type 2, 3, or 4 SMA aged 16 or older that show quantifiable motor deficits of the upper body. The investigators will then implant the subjects with percutaneous, linear spinal leads near the cervical spinal cord for a period of up to 29 days. Although these leads are not optimized for motor function but rather for their clinically approved indication of treating pain, the investigators believe they provide a safe technology enabling our team to perform scientific measurement necessary to evaluate potential for effects of SCS in motor paralysis with SMA. After the end of the study, the leads will be explanted.
The investigators plan to 1. verify that spinal cord stimulation increases elbow muscle strength in subjects with SMA, 2. verify that spinal cord stimulation improves motor control in subjects with SMA, 3. verify that spinal cord stimulation induces measurable changes in spinal circuits and motoneuron recruitment properties in the 29 day course of implantation.
61 studies on the registry are indexed under Spinal Muscular Atrophies of Childhood; 18 are open to participants now.
This study's enrollment of 3 is below the median of 15 across 41 interventional studies indexed under Spinal Muscular Atrophies of Childhood.
Browse Spinal Muscular Atrophies of Childhood studies →Marco Capogrosso is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Compared within Spinal Muscular Atrophies of Childhood, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Muscular Atrophy, Spinal. The counts are of registry records indexed under each term, refreshed daily. How we classify →
SMA Participant Inclusion Criteria:
Subject is diagnosed as being non-ambulatory SMA based on the following criteria:
a. Can't stand independently.
Healthy Control Participant Inclusion Criteria:
SMA Participant Exclusion Criteria:
Healthy Control Participant Exclusion Criteria:
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the cervical epidural (C4-T1 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
Device: Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)
Spinal cord stimulation is FDA approved for treatment of pain. We are proposing utilizing the same technology to help restore motor control in people who have declining function due to the progression of SMA. These are 2-4 leads that are FDA-approved.
Number and Severity of Adverse Events
Success Criteria: no serious adverse events related to the stimulation or intolerable. adverse events reported
Time frame: 29 days
Muscle Weakness Muscle Activation
Muscle activation: measure surface electromyogram (EMGs) produced by the subjects during isometric movements of the elbow in the HUMAC Norm and compare to SCS-on with SCS-off and non-affected SCS side performances. Meaningful Change: \>20% EMG root-mean-square (RMS) compared to SCS-on.
Time frame: 29 days
Motor Function ROM
Range of Motion (ROM): Meaningful Change: Increase of \>20% of the elbow joint (if available) during SCS-on against SCS-off and SCS-non affected arm as measured by the HUMAC Norm during single-joint isotonic trials.
Time frame: 29 days
Motor Function RULM
The Revised Upper Limb Module (RULM) for SMA is a further refined version of the Hammersmith Functional Motor Scale Extended and includes specific items focused on upper-limb motor control such as raising the arms above the head that are particularly relevant for the Type 2 population of the study, or those with further progressed Type 3 and Type 4. The scale is a performance evaluation with a total score ranging from 0, if none of the activities is achieved, to 37, if all the activities are achieved fully, so a higher score means a better outcome. For our study, we require participants to score at least a 4 to be eligible. Meaningful Change: ≥2 point improvement. Compare outcomes between SCS-on and SCS-off as well as the non-affected arm.
Time frame: 29 days
Motor Function Fatigue
Fatigue will be assessed during motor function tests. Patients will be asked to provide a score from 1-10, where a greater number indicates a greater amount of fatigue for each stimulation configuration.
Time frame: 29 days
Discomfort/Pain
Patients will be asked to provide a score from 1-10, where a greater number indicates a greater amount of discomfort for each stimulation configuration. Spinal cord stimulation produces tingling sensations and other type of sensory phenomena. It is important to document that stimulation intensities required to improve motor function remain within a range of non-painful sensations.
Time frame: 29 days
Sensorimotor Network Structure Density
The investigators will perform high-definition weighted imaging to quantify fractional anisotropy as a measurement of axon density in the brain and spinal cord pre and post study.
Time frame: 29 days
Impression
The investigators will collect subjects and therapist feedback on how the technology is performing and what they would want to modify using The Clinical Global Impression Scale, a scale of 1-7 where a lower number indicates better performance and a higher number indicates more greatly impacted by their disease.
Time frame: 29 days
Sensorimotor Network Structure Integrity
The investigators will perform high-definition diffusion weighted imaging to quantify fractional anisotropy as a measurement of axon integrity in the brain and spinal cord pre and post study.
Time frame: 29 days
Sensorimotor Network Function
The investigators will perform resting state and motor-task functional MRI of the brain and spinal cord to quantify neural network activation at rest and during the execution of simple motor task such as leg muscle contraction.
Time frame: 29 days
Cortico-spinal Tract Integrity
The investigators will measure muscle evoked potential consequent to Transcranial Magnetic Stimulation of the cortico-spinal tract to assess the integrity of the cortico-spinal tract.
Time frame: 29 days
Spinal Circuit Excitability
The investigators will measure H-reflexes of the arm muscles to quantify excitability of spinal motoneurons to stimulation of primary sensory afferents pre and post-study. Expected Result: Our main scientific hypothesis is that SCS will restore monosynaptic responses of weak spinal motoneurons, thus increasing H-reflex responses pre and post study.
Time frame: 29 days
Motoneuron Firing Rates
The investigators will use high-density EMGs on leg muscles to calculate firing rates of single spinal motoneuron discharge during isometric maximal voluntary contractions.
Time frame: 29 days
Motor Firing Number
The investigators will use high-density EMGs on arm muscles to calculate the number of firing rates of single spinal motoneuron discharge during isometric maximal voluntary contractions.
Time frame: 29 days
Muscle Weakness Torque
Isometric torque: measure the isometric torque produced by the subject at the elbow during flexion and extension as well as grip function during hand held dynamometer as well as during wrist flexion and extension. The investigators will use the measurement of isometric torque to determine the changes in muscle strength for each participant with SCS on and with SCS off. This comparison will also include testing the non-affected arm to give the investigators a baseline for normal movement of the joint being tested. Success Criteria: ≥30% increased torque production over the SCS-off/non-affected baseline as measured during single-joint isometric torque.
Time frame: 29 days
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification, may be shared with other researchers for the purpose of data analysis and collaboration.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will become available at the end of the trial upon publication of the first manuscript. Estimation is 2 years from enrollment of first participant.
Access criteria: Data must be directly requested to the PI and will be shared upon completion of necessary data sharing agreement to protect confidential patient information.
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Oct 2026, 28 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2029 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spinal Muscular Atrophies of Childhood →